kit (An der Grub, Vienna, Austria), Optilyse B lysing solution (Immunotech, Marseille, France), and ORTHO PermeaFix reagent (Ortho Diagnostic Systems, Raritan, NJ, USA) were compared for their effects on light scatter patterns, and intracellular staining results as well as for the complexity and duration of the method. The detectability of intracellular antigens was tested, ie terminal deoxynucleotidyl transferase (TdT), cytoplasmic CD3 (CyCD3), myeloperoxidase (MPO) and cytoplasmic immunoglobulin (CyIg). The choice of these antigens was based on their relevance in the immunophenotyping of leukemias and lymphomas. 2,3 It was concluded from this study that in addition to Fix & Perm and PermeaFix, 3 also OptiLyse B and FACS Lysing Solution 4,5 allow a reliable detection of TdT, although the latter solutions were designed for lysed whole blood stainings. In contrast, CyCD3 and CyIgL were best detected with solutions especially developed for detection of intracellular antigen, ie Fix & Perm and Permeafix. [5] [6] [7] Fix & Perm turned out to be the only reagent that could reliably detect MPO. Therefore Fix & Perm was the only fixation-permeabilization solution, which allowed reliable detection of all four intracellular antigens tested.
Since flow cytometric detection of intracellular antigens is essential for immunophenotyping of leukemia and lymphomas, we feel that appropriate fixation-permeabilization solutions should be widely available for immunodiagnostic laboratories at low costs. Therefore, we tested a new solution (IntraPrep Permeabilization reagent; Immunotech) and the solutions which were routinely used in our laboratory, ie FACS Lysing Solution for the TdT staining and Fix & Perm for CyCD3, CyIgL and MPO staining.
Comparable to the Fix & Perm cell permeabilization reagent, IntraPrep consists of separate fixation and permeabilization solutions. The staining procedure using IntraPrep is similar to the procedure used with Fix & Perm and could as easily be introduced in our laboratory. Like the other four previously tested fixation-permeabilization procedures, the staining procedure with IntraPrep had only minor effects on light scatter patterns of bone marrow (BM) and peripheral blood (PB) samples when compared with untreated cell samples. Table 1 .
In conclusion, the flow cytometric detection of the intracellular antigens TdT, CyCD3, and MPO can reliably be performed with IntraPrep. This new permeabilization reagent turns out to be fully comparable to Fix & Perm with respect to the complexity and duration of the staining method as well as for the intracellular staining results. When compared to FACS Lysing Solution for the detection of TdT, the use of IntraPrep gave comparable staining results but the procedure is more time-consuming and requires more monoclonal antibodies to obtain similar results. Based on these data, we conclude that IntraPrep is a good alternative for Fix & Perm. 
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G-CSF treatment in acute leukemia
TO THE EDITOR
The articles by Terpstra and Lö wenberg and Rowe and Liesveld briefly touched on the use of granulocyte colony-stimulating factor (G-CSF) alone in the induction of remission in relapsed patients with myeloid leukemia and myelodysplasia following allogeneic bone marrow transplantation (BMT).
1-2
Encouraging results obtained in a limited number of patients and the changes observed at the cellular level during response might not only make this approach a therapeutic option for patients with leukemic relapse following BMT but also contribute to a better understanding of the biology of this heterogeneous disorder.
A 3-year-old Caucasian female patient was diagnosed with CALLA-positive, B precursor acute lymphoblastic leukemia (ALL) with normal cytogenetics and was treated with chemotherapy between 1985 and 1989. In 1993 she had a systemic relapse with a clonal cytogenetic abnormality [46,XX, der(3) t(1;3;11) (p36;p11;p11), add(2)(q29), del(6)(q15), del(12) (p12)]. At that time blast cells were CD19 and HLA-DR positive, CD10 negative and coexpressed myeloid markers (CD13 and CD33). She achieved and remained in remission with etoposide-containing chemotherapy until she was diagnosed with acute myeloid leukemia (AML) in April 1996. Leukemic cells carried the same cytogenetic abnormality, were Sudan black positive, CD19 positive, CD10 negative and strongly expressed myeloid markers. A fluorescence in situ hybridization (FISH) analysis was negative for MLL gene rearrangement.
Following remission induction and consolidation she had a matched unrelated BMT from a male donor in September 1996, conditioned with busulphan, cytarabine and cyclophosphamide. Bone marrow recovery was of donor origin as confirmed by FISH using X and Y chromosome-specific probes. She developed mild skin and gut graft-versus-host disease (GVHD). However, the response was short-lived as she experienced an early post-BMT relapse of recipient origin with the same clonal cytogenetic abnormality and 46% blasts in the bone marrow on day +100 in December 1996.
A second transplant and systemic chemotherapy were refused and after discontinuing cyclosporine she was started on G-CSF, 5 g/kg/day subcutaneously, according to the report by Giralt et al. 3 A dramatic response was observed with remission induction at the end of 3 weeks of treatment with the disappearance of the abnormal clone. FISH analysis of bone marrow cells revealed 100% male cells and she continued to have mild gut GVHD.
She remained in complete clinical remission until May 1997 when she had an isolated left breast recurrence with blast cells carrying the same, biphenotypic surface markers, this time with additional CD10 positivity. Bone marrow cells were shown to be of donor origin by FISH analysis. Breast mass dramatically responded to dexamethasone treatment in a week. The patient had a Karnofsky score of 100%, was induced with chemotherapy and is being prepared for a second transplant.
Several possible explanations have been proposed for G-CSF-induced remission induction and durable remissions in relapsed AML patients following allogeneic BMT.
3 Both decreased and increased levels of endogenous G-CSF have been reported in AML. 4 The decreased levels may represent a negative feedback control mechanism or an inhibition of the hemopoietic inductive microenvironment by the mediators released from leukemic cells and may play a major role in the suppression of the normal hemopoiesis. Given the heterogeneous nature of AML, it may be reasonable to think that some patients with low G-CSF levels may benefit from pharmacological doses of G-CSF. Once normal hemopoiesis is established, suppression of malignant hemopoiesis by physical and biological means, by graft-versus-leukemia effect in post-BMT cases, may ensue. In some patients with myelodysplastic syndromes, G-CSF treatment has been shown to produce a superior stimulatory effect for normal hemopoietic cells resulting in the increase of normal neutrophils. 5 Thus, the selective or superior stimulation of donor hemopoiesis and subsequent inhibition of malignant growth with or without apoptosis-inducing effects of growth factor on the malignant clone seems to be a plausible explanation in our case. A similar response has also been reported in a BCR-ABL-positive ALL patient. 6 An interesting aspect of our case is the isolated breast relapse while the bone marrow is still of donor origin. This can hypothetically be explained by the scarcity of donor cells in the involved extramedullary tissue, in this case breast, resulting in a lack of local anti-leukemia influence of the donor cells as suggested previously by us. 7 We think that growth factor treatment alone or in combination with immunostimulatory compounds may be an option for selected relapsed leukemia patients following allogeneic BMT.
